PTPRCAP — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5828349	1.00	2/20
SCHEMBL6164741	1.00	2/20
Anonaine (SCHEMBL15800852)	1.00	2/20
Anonaine (SCHEMBL15800856)	1.00	2/20
SCHEMBL5828563	0.85	2/20
SCHEMBL5828564	0.85	2/20
SCHEMBL5827668	0.79	2/20
SCHEMBL5827669	0.79	2/20
SCHEMBL5828641	0.79	2/20
SCHEMBL5828642	0.79	2/20
SCHEMBL5829011	0.79	2/20
SCHEMBL5829012	0.79	2/20
SCHEMBL9976807	0.76	2/20
Xylopine (SCHEMBL2595968)	0.69	2/20
Xylopine (SCHEMBL6686161)	0.69	2/20
SCHEMBL6689417	0.65	2/20
SCHEMBL1914213	0.63	2/20
SCHEMBL1914215	0.63	2/20
SCHEMBL5828126	0.63	2/20
SCHEMBL12257833	0.62	2/20

Clinical trials — most relevant to PTPRCAP by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance	PHASE4	UNKNOWN
Regulatory Lymphocytes in Patients Treated With Specific Immunotherapy	PHASE4	COMPLETED
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation	PHASE2	UNKNOWN
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Imatinib in Dermatofibrosarcoma Protuberans (DFSP)	PHASE1/PHASE2	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Cyclosporine For The Treatment Of COVID-19(+)	PHASE2	COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	PHASE1	COMPLETED
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)	PHASE1	COMPLETED
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure	nan	UNKNOWN
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes	nan	RECRUITING
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
Evaluation of the Level of Expression of CD45RC on T Lymphocytes as a Predictive Biomarker of Acute Rejection After Renal Transplantation	nan	RECRUITING
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children	nan	NOT_YET_RECRUITING
Ruxolitinib in Patients With Myelofibrosis	nan	UNKNOWN
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)	nan	NOT_YET_RECRUITING
Using of Costimulatory and co Inhibatory Immune Checkpoints as Diagnostic and Prognostic in Breast Cancer	nan	UNKNOWN
Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms	nan	NOT_YET_RECRUITING
Study of Proteins in Head and Neck Cancer Cells	nan	COMPLETED
Clinically Actionable Tumor-Associated Antigens in Prostate Cancer	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PTPRCAP binder may also engage these)

Protein	Name	Similarity
Q64697	—	1.000	Q64697 →
A0A2R8YCJ5	—	0.993	A0A2R8YCJ5 →
Q9NQX5	—	0.990	Q9NQX5 →
A0A8I3PMN2	—	0.988	A0A8I3PMN2 →
Q5BK39	—	0.987	Q5BK39 →
LMTK3	Serine/threonine-protein kinase LMTK3	0.985	landscape →
Q8TER5	—	0.983	Q8TER5 →
Q7TN12	—	0.983	Q7TN12 →
A2A9F4	—	0.983	A2A9F4 →
A0AAU7VAE8	—	0.983	A0AAU7VAE8 →
Q8K1T1	—	0.982	Q8K1T1 →
D4A9R4	—	0.982	D4A9R4 →
Q96RJ3	—	0.982	Q96RJ3 →
Q8TEF2	—	0.982	Q8TEF2 →
A6NLX4	—	0.982	A6NLX4 →
Q8MII8	—	0.982	Q8MII8 →
A2A699	—	0.982	A2A699 →
Q9Y4B5	—	0.982	Q9Y4B5 →
Q8K330	—	0.982	Q8K330 →
P98162	—	0.981	P98162 →
P27106	—	0.981	P27106 →
Q3KP66	—	0.981	Q3KP66 →
Q96B54	—	0.981	Q96B54 →
Q8VC98	—	0.981	Q8VC98 →
Q96PX9	—	0.981	Q96PX9 →
Q6QNY0	—	0.981	Q6QNY0 →
A5A769	—	0.981	A5A769 →
Q5XJV6	—	0.981	Q5XJV6 →
Q64322	—	0.981	Q64322 →
Q0VD38	—	0.981	Q0VD38 →